| 產(chǎn)品名稱 | Saos-2 |
|---|---|
| 商品貨號 | B165663 |
| Organism | Homo sapiens, human |
| Tissue | bone |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | osteosarcoma |
| Age | 11 years |
| Gender | female |
| Ethnicity | Caucasian |
| Applications | This cell line is suitable as a transfection host |
| Karyotype | The stemline chromosome number is hypotriploid with the modal number of 56 chromosomes per cell and the 2S component occurring at 13.2%. Over two-thirds of the chromosome complement consisted of structurally rearranged chromosomes., Most marker chromosomes had complex rearrangements. The origin of the segments composing these markers could not be identified. Of the identifiable markers, 6p+/q+, 7p+, 11p+, and 12p+ occasionally were present at 2 copies per cell., The Y chromosome was not detected in the QM stained preparation. |
| Images |  |
| Derivation | This is one of an extensive series of human tumor lines isolated and characterized by J. Fogh and G. Trempe. |
| Clinical Data | 11 years Caucasian female The patient was treated with RTG, methotrexate, adriamycin, vincristine, cytoxan, and aramycin-C. |
| Antigen Expression | Antigen expression: Blood Type B, Rh+; HLA A2, A3, Bw16, Bw47 |
| Receptor Expression | epidermal growth factor (EGF); transforming growth factor beta (type 1 and type 2) |
| Tumorigenic | No |
| Effects | No, The cells were not tumorigenic in immunosuppressed mice, but did form colonies in semisolid medium. |
| Comments | The patient was treated with RTG, methotrexate, adriamycin, vincristine, cytoxan, and aramycin-C. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified , Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
|
| Subculturing | Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommendedMedium Renewal: 1 to 2 times per week |
| Cryopreservation | Culture medium, 95%; DMSO, 5% |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile | Amelogenin: X CSF1PO: 10 D13S317: 12,13 D16S539: 12,13 D5S818: 12 D7S820: 8,10 THO1: 6,9 TPOX: 8 vWA: 18 |
| Isoenzymes | AK-1, 1 ES-D, 2 G6PD, B GLO-I, 2 Me-2, 1 PGM1, 1-2 PGM3, 1-2 |
| Name of Depositor | J Fogh, G Trempe |
| Deposited As | Homo sapiens |
| References | Banerjee C, et al. An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteoclacin gene. Proc. Natl. Acad. Sci. USA 93: 4968-4973, 1996. PubMed: 8643513 Fogh J. Human tumor cells in vitro. New York: Plenum Press; 1975. Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034 Takeuchi Y, et al. Relationship between actions of transforming growth factor (TGF)-beta and cell surface expression of its receptors in clonal osteoblastic cells. J. Cell. Physiol. 162: 315-321, 1995. PubMed: 7860639 Zhang W, et al. EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells. J. Cell. Physiol. 162: 348-358, 1995. PubMed: 7860643 Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 Schar BK, et al. Simultaneous detection of all four alkaline phosphatase isoenzymes in human germ cell tumors using reverse transcription-PCR. Cancer Res. 57: 3841-3846, 1997. PubMed: 9288797 Morris GF, et al. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 93: 895-899, 1996. PubMed: 8570655 Werner H, et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 93: 8318-8323, 1996. PubMed: 8710868 Wang X, et al. Variabilin, a novel RGD-contining antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the gard tick Dermacentor variabilis. J. Biol. Chem. 271: 17785-17790, 1996. PubMed: 8663513 Karnieli E, et al. The IGF-1 receptor gene promoter is a molecular target for the Ewing's Sarcoma=Wilms' Tumor 1 fusion protein. J. Biol. Chem. 271: 19304-19309, 1996. PubMed: 8702614 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
